Pfizer Completes Acquisition of Therachon
July 01, 2019
July 01, 2019
NEW YORK, July 1 -- Pfizer, a pharmaceutical company, issued the following news release:
* * *
- Early clinical development program for achondroplasia augments Pfizer's Rare Disease portfolio
* * *
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with . . .
* * *
- Early clinical development program for achondroplasia augments Pfizer's Rare Disease portfolio
* * *
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with . . .